The 2026 clinical review of molecular hydrogen: what the human data show
A major 2026 review in Frontiers in Pharmacology (doi 10.3389/fphar.2026.1884091) comprehensively summarizes clinical trials of molecular hydrogen (H2) across organ systems — the kind of evidence inventory the hydrogen field has needed. Its mitochondrial findings are detailed, and its caveats are blunt.
What does the review say hydrogen does at the mitochondrial level?
Key mechanisms summarized: H2 diffuses into neuronal mitochondria and nuclei; acts via Nrf2/HO-1 antioxidant signaling; helps restore the balance of mitochondrial fission and fusion; promotes biogenesis and PINK1/Parkin mitophagy (the cleanup of damaged mitochondria); and inhibits the cGAS-STING-IRF3 inflammatory pathway. That is a genuinely mitochondrial story — not just generic antioxidant marketing.
What are the limits?
The authors themselves note that large trials remain inconsistent and that mechanisms are incompletely clarified. Antioxidant and anti-inflammatory effects are the most established; disease-modifying clinical benefit remains unproven.
How does this connect to mitochondrial health?
Fission/fusion balance, biogenesis and mitophagy are three of the four pillars of mitochondrial quality control. H2 touches all of them in the summarized literature — which is why the hydrogen watch continues on this site, with the inconsistency of large trials kept front and center.
Where the evidence stands
- Established: Molecular hydrogen's antioxidant and anti-inflammatory effects are the best-supported effects in the review.
- Emerging: Mitochondrial mechanisms — fission/fusion balance, biogenesis, PINK1/Parkin mitophagy — are supported by summarized studies but not settled.
- Preliminary: Clinical disease-modifying benefit from hydrogen therapy remains unproven; the authors flag inconsistent large trials.